What Is Dulaglutide?

1. The Short Answer

Dulaglutide is the active ingredient in Trulicity, a prescription GLP-1 receptor agonist injection from Lilly. The current DailyMed Trulicity label identifies the product as Trulicity, dulaglutide injection, for subcutaneous use.

DailyMed states Trulicity is indicated with diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. The label also includes reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.

The official Trulicity site uses similar consumer-facing language: Trulicity is for adults and children 10 years and older with type 2 diabetes to improve blood sugar, and it is also used in adults with type 2 diabetes to reduce the risk of major cardiovascular events in people with heart disease or multiple cardiovascular risk factors.

2. Dulaglutide vs Trulicity

Dulaglutide is the molecule. Trulicity is the brand.

This is the same naming pattern used across many GLP-1s. Liraglutide is the active ingredient associated with Victoza and Saxenda. Semaglutide is the active ingredient associated with Ozempic, Wegovy, and Rybelsus. Tirzepatide is the active ingredient associated with Mounjaro and Zepbound.

3. Why Dulaglutide Is Part of the GLP-1 Category

Dulaglutide belongs in the GLP-1 category because the current Trulicity label describes it as a glucagon-like peptide-1 receptor agonist. For broader terminology, see What Is a GLP-1?.

“GLP-1” can refer to the natural hormone, the receptor pathway, the medication class, a brand family, or a loose public shorthand for newer metabolic medicines. Dulaglutide is a specific active ingredient within that broader shorthand.

NCBI Bookshelf’s GLP-1 receptor agonist class overview places dulaglutide alongside other GLP-1 receptor agonists and describes it as a once-weekly medication. The same source distinguishes tirzepatide because current tirzepatide labels use both GIP and GLP-1 receptor language.

4. The U.S. Label Context: Type 2 Diabetes and Defined Cardiovascular Risk

The current U.S. Trulicity label focuses on type 2 diabetes. It describes Trulicity as used with diet and exercise to improve glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes mellitus.

The label also includes a cardiovascular-risk reduction indication. DailyMed states that Trulicity is indicated to reduce the risk of major adverse cardiovascular events (defined as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.

Lilly originally announced Trulicity’s FDA approval in September 2014 as a once-weekly therapy for adults with type 2 diabetes. In February 2020, Lilly announced the additional FDA approval of Trulicity for reducing major adverse cardiovascular events in adults with type 2 diabetes who meet specific cardiovascular criteria.

5. Dulaglutide vs Liraglutide

Dulaglutide and liraglutide are different active ingredients pointing to different brand families.

Liraglutide is associated with Victoza and Saxenda, while dulaglutide is associated with Trulicity. Trulicity is described in its label as a once-weekly injection. Victoza and Saxenda are described as once-daily injections.

For the molecule-level version of that comparison, see What Is Liraglutide?. For brand-specific context, see What Is Victoza? and What Is Saxenda?.

6. Dulaglutide vs Semaglutide

Dulaglutide and semaglutide are different active ingredients. Trulicity contains dulaglutide. Ozempic, Wegovy, and Rybelsus contain semaglutide.

Semaglutide appears in multiple product forms and label contexts: Ozempic is centered on type 2 diabetes labeling, Wegovy is centered on weight-management contexts, and Rybelsus is an oral semaglutide for type 2 diabetes.

For semaglutide-specific background, see What Is Semaglutide?.

7. Dulaglutide vs Tirzepatide

Dulaglutide and tirzepatide are different active ingredients with different receptor wording in their respective U.S. labels. Trulicity contains dulaglutide and is described as a GLP-1 receptor agonist. Mounjaro and Zepbound contain tirzepatide and are described as GIP and GLP-1 receptor agonists.

8. Why Dulaglutide Naming Gets Confusing

Dulaglutide naming can be confusing because the molecule (dulaglutide), the brand (Trulicity), and the class (GLP-1) are frequently used interchangeably in public discussions.

To clarify: Dulaglutide is the active ingredient in Trulicity. Current U.S. label sources describe Trulicity as a once-weekly GLP-1 receptor agonist injection indicated for type 2 diabetes and defined cardiovascular-risk contexts.

Decisions regarding starting, stopping, or switching these medications require an evaluation of personal medical context and should be discussed directly with a qualified healthcare provider.

9. What Is Dulaglutide FAQ

• What is dulaglutide in simple terms?

  Dulaglutide is an active ingredient used in Trulicity, a prescription GLP-1 receptor agonist injection. Current U.S. label sources describe Trulicity as a once-weekly product used in type 2 diabetes and defined cardiovascular-risk contexts.

• Is dulaglutide the same as Trulicity?

  No. Dulaglutide is the active ingredient, while Trulicity is the Lilly brand name.

• Is dulaglutide a GLP-1 receptor agonist?

  Yes. The current DailyMed label describes Trulicity, dulaglutide injection, as a glucagon-like peptide-1 receptor agonist.

• How is dulaglutide different from liraglutide, semaglutide, and tirzepatide?

  They are different active ingredients. Dulaglutide is associated with Trulicity, liraglutide with Victoza and Saxenda, semaglutide with Ozempic, Wegovy, and Rybelsus, and tirzepatide with Mounjaro and Zepbound.

10. Sources